DE60220325D1 - Substituierte Carbostyrilderivate als 5-HT1A-Subtyp Agonisten - Google Patents

Substituierte Carbostyrilderivate als 5-HT1A-Subtyp Agonisten

Info

Publication number
DE60220325D1
DE60220325D1 DE60220325T DE60220325T DE60220325D1 DE 60220325 D1 DE60220325 D1 DE 60220325D1 DE 60220325 T DE60220325 T DE 60220325T DE 60220325 T DE60220325 T DE 60220325T DE 60220325 D1 DE60220325 D1 DE 60220325D1
Authority
DE
Germany
Prior art keywords
carbostyril derivatives
subtype agonists
substituted carbostyril
ht1a subtype
ht1a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60220325T
Other languages
English (en)
Other versions
DE60220325T2 (de
Inventor
Yasufumi Uwahodo
Shaun Jordan
Tetsuro Kikuchi
Katsura Tottori
Tsuyoshi Hirose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25087808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60220325(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of DE60220325D1 publication Critical patent/DE60220325D1/de
Application granted granted Critical
Publication of DE60220325T2 publication Critical patent/DE60220325T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE60220325T 2001-01-29 2002-01-29 Substituierte Carbostyrilderivate als 5-HT1A-Subtyp Agonisten Expired - Lifetime DE60220325T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77021001A 2001-01-29 2001-01-29
US770210 2001-01-29

Publications (2)

Publication Number Publication Date
DE60220325D1 true DE60220325D1 (de) 2007-07-05
DE60220325T2 DE60220325T2 (de) 2008-01-17

Family

ID=25087808

Family Applications (3)

Application Number Title Priority Date Filing Date
DE60239711T Expired - Lifetime DE60239711D1 (de) 2001-01-29 2002-01-29 Substituierte Carbostyrilderivate als 5-HT1A-Subtyp Agonisten zur Behandlung von bipolarer Störung
DE60210581T Expired - Lifetime DE60210581T2 (de) 2001-01-29 2002-01-29 Substituierte carbostyrilderivate als 5-ht1a-subtyp agonisten
DE60220325T Expired - Lifetime DE60220325T2 (de) 2001-01-29 2002-01-29 Substituierte Carbostyrilderivate als 5-HT1A-Subtyp Agonisten

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE60239711T Expired - Lifetime DE60239711D1 (de) 2001-01-29 2002-01-29 Substituierte Carbostyrilderivate als 5-HT1A-Subtyp Agonisten zur Behandlung von bipolarer Störung
DE60210581T Expired - Lifetime DE60210581T2 (de) 2001-01-29 2002-01-29 Substituierte carbostyrilderivate als 5-ht1a-subtyp agonisten

Country Status (20)

Country Link
EP (3) EP1355639B1 (de)
JP (4) JP4178032B2 (de)
KR (5) KR100825705B1 (de)
CN (3) CN1879624A (de)
AR (4) AR032641A1 (de)
AT (3) ATE362763T1 (de)
AU (4) AU2002226752C1 (de)
BR (1) BR0206237A (de)
CA (2) CA2429496C (de)
CY (3) CY1105631T1 (de)
DE (3) DE60239711D1 (de)
DK (3) DK1712225T3 (de)
ES (3) ES2286755T3 (de)
HK (2) HK1061805A1 (de)
MX (2) MXPA03006603A (de)
MY (1) MY129355A (de)
PH (1) PH12014500937A1 (de)
PT (3) PT1621198E (de)
TW (2) TWI331919B (de)
WO (1) WO2002060423A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
CA2529857A1 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
MXPA05006857A (es) 2002-12-27 2005-08-18 Otsuka Pharma Co Ltd Derivados de carbostirilo e inhibidores de la recaptacion de serotonina para el tratamiento de desordenes en el humor.
CN102172402A (zh) 2003-05-23 2011-09-07 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
WO2006090273A2 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
PL1912650T3 (pl) * 2005-08-03 2018-01-31 Sprout Pharmaceuticals Inc Zastosowanie flibanseryny w leczeniu otyłości
TW200848041A (en) * 2007-03-30 2008-12-16 Otsuka Pharma Co Ltd A medicament for treating schizophrenia comprising cilostazol
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
JP2009286740A (ja) * 2008-05-30 2009-12-10 Otsuka Pharmaceut Co Ltd アリピプラゾールを含有する逆耐性抑制剤
EP2338873A1 (de) 2009-12-22 2011-06-29 Gmeiner, Peter Neue Aminotetralinderivate
AR090245A1 (es) 2012-03-06 2014-10-29 Otsuka Pharma Co Ltd Preparacion solida oral de liberacion sostenida, metodo de preparacion
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5646812A (en) * 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
DE3721799C2 (de) 1986-07-01 1993-12-23 Mitsubishi Electric Corp Integrierte Redox-Bauelementschaltung und Verfahren zum Herstellen
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
WO1992020655A1 (en) * 1991-05-20 1992-11-26 The Upjohn Company Carboxamido-(1,2n)-carbocyclic-2-aminotetralin derivatives
US5532240A (en) * 1991-12-26 1996-07-02 Yoshitomi Pharmaceutical Industries, Ltd. Condensed thiophene compound and pharmaceutical use thereof
AU5446894A (en) * 1992-10-23 1994-05-24 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
DK148292D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Forbindelser
JP2959615B2 (ja) * 1993-06-24 1999-10-06 吉富製薬株式会社 縮合型チオフェン化合物およびその医薬用途
JPH09291034A (ja) * 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US5688950A (en) * 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
WO1997042190A1 (en) * 1996-05-07 1997-11-13 Pfizer Inc. Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist
JP4012994B2 (ja) * 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
DE69719765T2 (de) * 1996-08-27 2003-10-16 Wyeth Corp 4-aminoethoxy-indolderivate als dopamin d2 agonisten und als 5ht1a liganden
CA2317515A1 (en) * 1998-02-03 1999-08-05 Frances Christy Nelson Oxazole derivatives as serotonin-1a receptor agonists
ZA992670B (en) * 1998-04-13 2000-10-12 American Home Prod 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists.
JPH11335286A (ja) * 1998-05-25 1999-12-07 Mitsui Chem Inc ドーパミン拮抗薬の効果増強剤
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
DK1397145T3 (da) * 2001-06-19 2007-01-02 Norbert Mueller Anvendelse af COX-2-inhibitorer til behandling af schizophrenia eller tics-lidelser
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma

Also Published As

Publication number Publication date
DK1621198T3 (da) 2007-09-24
KR100825705B1 (ko) 2008-04-29
AU2002226752B2 (en) 2005-03-17
AU2005201772A1 (en) 2005-05-19
ES2363366T3 (es) 2011-08-02
JP4178032B2 (ja) 2008-11-12
CA2429496A1 (en) 2002-08-08
WO2002060423A2 (en) 2002-08-08
CA2700314A1 (en) 2002-08-08
JP4896831B2 (ja) 2012-03-14
DK1355639T3 (da) 2006-08-14
KR20030065570A (ko) 2003-08-06
EP1621198A3 (de) 2006-04-12
AR099754A2 (es) 2016-08-17
DE60239711D1 (de) 2011-05-19
KR100653591B1 (ko) 2006-12-05
KR100763288B1 (ko) 2007-10-04
AR032641A1 (es) 2003-11-19
ATE362763T1 (de) 2007-06-15
JP2007297405A (ja) 2007-11-15
MX344556B (es) 2016-12-20
EP1355639B1 (de) 2006-04-12
ES2261652T3 (es) 2006-11-16
AU2005201772C1 (en) 2010-06-03
TWI302832B (en) 2008-11-11
JP2011225587A (ja) 2011-11-10
AU2007201701A1 (en) 2007-05-10
KR100713607B1 (ko) 2007-05-02
CN1813745A (zh) 2006-08-09
CN100450485C (zh) 2009-01-14
DE60210581D1 (en) 2006-05-24
HK1091403A1 (en) 2007-01-19
KR20070065425A (ko) 2007-06-22
ATE322894T1 (de) 2006-04-15
AU2007201701B2 (en) 2010-06-17
JP2011184460A (ja) 2011-09-22
EP1621198A2 (de) 2006-02-01
PT1621198E (pt) 2007-06-08
AU2002226752C1 (en) 2010-02-18
ATE504293T1 (de) 2011-04-15
MY129355A (en) 2007-03-30
CN1879624A (zh) 2006-12-20
EP1355639A2 (de) 2003-10-29
EP1712225B1 (de) 2011-04-06
PT1712225E (pt) 2011-04-18
PH12014500937A1 (en) 2015-09-21
PT1355639E (pt) 2006-06-30
EP1712225A1 (de) 2006-10-18
MXPA03006603A (es) 2004-02-12
KR20060085260A (ko) 2006-07-26
KR100601073B1 (ko) 2006-07-19
CN1239154C (zh) 2006-02-01
WO2002060423A3 (en) 2003-04-10
TWI331919B (en) 2010-10-21
CN1484524A (zh) 2004-03-24
DK1712225T3 (da) 2011-06-20
HK1061805A1 (en) 2004-10-08
AU2005201772B2 (en) 2007-05-17
CA2429496C (en) 2010-10-19
TW200522960A (en) 2005-07-16
DE60220325T2 (de) 2008-01-17
AR080849A2 (es) 2012-05-09
AU2009233591A1 (en) 2009-11-19
JP2004517937A (ja) 2004-06-17
CA2700314C (en) 2012-04-24
EP1621198B1 (de) 2007-05-23
CY1108031T1 (el) 2013-09-04
KR20060028485A (ko) 2006-03-29
KR20050107822A (ko) 2005-11-15
ES2286755T3 (es) 2007-12-01
JP5683010B2 (ja) 2015-03-11
CY1105631T1 (el) 2010-12-22
AR079761A2 (es) 2012-02-15
AU2009233591B2 (en) 2011-10-20
DE60210581T2 (de) 2007-04-05
BR0206237A (pt) 2003-12-23
CY1111392T1 (el) 2015-08-05

Similar Documents

Publication Publication Date Title
ATE362763T1 (de) Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten
ATE441631T1 (de) Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer
ATE370137T1 (de) 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren
ATE392897T1 (de) Chinolinderivate als npy antagonisten
ATE377419T1 (de) Substituierte 4-alkoxyoxazol derivate als ppar agonisten
ATE309996T1 (de) Chinolinonderivate als tyrosin-kinase inhibitoren
IS8439A (is) Nýjar kínólín afleiður
ATE414067T1 (de) Guanidinobenzamide als mc4-r agonisten
ATE370120T1 (de) Substituierte 2-pyridin-cyclohexan-1,4- diaminderivate
DE60308850D1 (de) Pyridinoylpiperidine als 5-ht1f agonisten
DE60225563D1 (de) 4-amino-6-phenyl-pyrroloä2,3-düpyrimidin derivate
DK1427709T3 (da) 3-substituerede 4-pyrimidonderivater
NO20041235L (no) Kinolinderivater som neuropeptid Y antagonister
ATE312078T1 (de) 1-aryl-oder 1-alkylsulfonylbenzazol derivate als 5-hydroxytryptamin-6 liganden
ATE396191T1 (de) Azaindolylalkylaminderivate als 5- hydroxytryptamin-6-liganden
DE60203529D1 (de) Indolderivate als cox-ii-inhibitoren
ATE413879T1 (de) ß(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)- ETHYLAMINO)- PROPYLPHENYL-DERIVATE ALS BETA2 AGONISTEN
EE200300447A (et) Asendatud bensofuraan-2-karboksamiidide derivaadid
ATE428420T1 (de) Substituierte 8-arylchinoline als phosphodiesterase-4-hemmer
ATE395333T1 (de) 4-phenylpiperazinyl, -piperidinyl und - tetrahydropyridyl-derivate als dopamin d4- antagonisten
DE60207399D1 (de) Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten
ATE281435T1 (de) Phenyl-heterocyclyl-ether-derivate als serotonin re-uptake inhibitoren
ATE410428T1 (de) Pyrroloä2,1-cüä1,4übenzodiazepine als vasopressin-agonisten
DE60210058D1 (de) Alkoxycarbonylamino-heteroaryl-carbonsäurederivate als ip-antagonisten
DE60201463D1 (de) Indanon-Derivate als Duftstoffe

Legal Events

Date Code Title Description
8363 Opposition against the patent